Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.

Rissanen A, Howard CP, Botha J, Thuren T; Global Investigators.

Diabetes Obes Metab. 2012 Dec;14(12):1088-96. doi: 10.1111/j.1463-1326.2012.01637.x. Epub 2012 Jul 19.

PMID:
22726220
2.

Basal insulin and cardiovascular and other outcomes in dysglycemia.

ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11.

3.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

4.

[The secretion of adenosin 3',5'-monophosphate after hydrokinetic and ecbolic stimulation in the canine pancreas (author's transl)].

Teufel H, Boeckmann U.

Hoppe Seylers Z Physiol Chem. 1981 May;362(5):499-510. German.

PMID:
6265337

Supplemental Content

Loading ...
Support Center